Roche bets again on Ionis in Huntington’s, Alzheimer’s

Roche is again pair­ing up with its decade­long part­ner Io­n­is Phar­ma­ceu­ti­cals, pay­ing $60 mil­lion up­front for the ex­clu­sive rights to two RNA as­sets, the com­pa­nies said Wednes­day morn­ing.

The deal cen­ters around Hunt­ing­ton’s dis­ease and Alzheimer’s dis­ease. The duo orig­i­nal­ly came to­geth­er in 2013 for an­oth­er Hunt­ing­ton’s pro­gram, tomin­ersen, which is cur­rent­ly in a Phase II study, and again in 2018 for IgA nephropa­thy and a lead­ing cause of blind­ness known as ge­o­graph­ic at­ro­phy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.